Glenn M. Chertow:
ORCID: http://orcid.org/0000-0002-7599-0534
Role: ConceptualizationRole: InvestigationRole: MethodologyRole: Writing – original
draft
Geoffrey A. Block: Role: ConceptualizationRole: InvestigationRole: SupervisionRole: Writing – review
& editing
John F. Neylan: Role: ConceptualizationRole: Funding acquisitionRole: Project administrationRole:
ResourcesRole: Writing – review & editing
Pablo E. Pergola: Role: ConceptualizationRole: InvestigationRole: Writing – review & editing
Katrin Uhlig: Role: ConceptualizationRole: Project administrationRole: Writing – review & editing
Steven Fishbane: Role: ConceptualizationRole: InvestigationRole: Writing – review & editing
Rosa Maria Affonso Moysés: Role: Editor
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
Title:
PLoS ONE
Publisher:
Public Library of Science
(San Francisco, CA USA
)
ISSN
(Electronic):
1932-6203
Publication date
(Electronic):
29
November
2017
Publication date Collection: 2017
Volume: 12
Issue: 11
Electronic Location Identifier: e0188712
Affiliations
[1
]
Stanford University School of Medicine, Department of Medicine - Med/Nephrology, Stanford,
California, United States of America
[2
]
Denver Nephrology, Denver, Colorado, United States of America
[3
]
Keryx Biopharmaceuticals, Inc., Boston, Massachusetts, United States of America
[4
]
Renal Associates PA, San Antonio, Texas, United States of America
[5
]
Hofstra Northwell School of Medicine, Division of Medicine - Kidney Diseases and Hypertension,
Great Neck, New York, United States of America
Universidade Nove de Julho, BRAZIL
Author notes
Competing Interests: GMC has served as a consultant to Akebia, Amgen, AstraZeneca, Bristol-Myers Squibb,
Gilead, Keryx, and ZS Pharma, has ownership interest in Ardelyx, Durect, Outset, PuraCath
Medical, Physiowave, and Thrasos Therapeutics, has received research support from
Amgen, Janssen, the National Institute of Diabetes and Digestive and Kidney Diseases,
and the National Heart, Lung, and Blood Institute, and has received honoraria from
the American Society of Nephrology. GAB has served as a consultant for Akebia, Amgen,
Ardelyx, AstraZeneca, Celgene, Daiichi Sankyo, Keryx, Relypsa, Sanfit, and ZS Pharma,
has ownership interest in Ardelyx and Nephroceuticals, has received research support
from Keryx, and has received honoraria from Akebia, Amgen, AstraZeneca, Celgene, Daiichi
Sankyo, Keryx, and Sanofi. JFN and KU are employees of Keryx and have ownership interest
in Keryx. PEP has served as a consultant for Keryx, Relypsa, Sandoz, Vifor Pharma,
and ZS Pharma, and has received honoraria from Keryx, Relypsa, Sandoz, and ZS Pharma.
SF has served as a consultant for AstraZeneca, Keryx, Rockwell, and ZS Pharma, has
received research funding from Amgen, AstraZeneca, Janssen, and ZS Pharma, and has
received honoraria from AstraZeneca, Keryx, Rockwell, and ZS Pharma. This does not
alter our adherence to PLOS ONE policies on sharing data and materials.
Author information
Article
Publisher ID:
PONE-D-17-22064
DOI: 10.1371/journal.pone.0188712
PMC ID: 5706696
PubMed ID: 29186198
SO-VID: 63099ef5-152a-4d84-b255-b95e73714a8b
Copyright © © 2017 Chertow et al
License:
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited.
Funded by: keryx
GMC has served as a consultant to Akebia, Amgen, Ardea, AstraZeneca, Bristol-Myers
Squibb, Gilead, Keryx, and ZS Pharma, has ownership interest in Ardelyx, Durect, Outset,
PuraCath Medical, Physiowave, and Thrasos, has received research support from Amgen,
Janssen, the National Institute of Diabetes and Digestive and Kidney Diseases, and
the National Heart, Lung, and Blood Institute, and has received honoraria from the
American Society of Nephrology. GAB has served as a consultant for Akebia, Amgen,
Ardelyx, AstraZeneca, Celgene, Daiichi Sankyo, Keryx, Relypsa, Sanfit, and ZS Pharma,
has ownership interest in Ardelyx and Nephroceuticals, has received research support
from Keryx, and has received honoraria from Akebia, Amgen, AstraZeneca, Celgene, Daiichi
Sankyo, Keryx, and Sanofi. JFN and KU are employees of Keryx and have ownership interest
in Keryx. PEP has served as a consultant for Keryx, Relypsa, Sandoz, Vifor Pharma,
and ZS Pharma, and has received honoraria from Keryx, Relypsa, Sandoz, and ZS Pharma.
SF has served as a consultant for AstraZeneca, Keryx, Rockwell, and ZS Pharma, has
received research funding from Amgen, AstraZeneca, Janssen, and ZS Pharma, and has
received honoraria from AstraZeneca, Keryx, Rockwell, and ZS Pharma. The phase 2 and
phase 3 clinical trials and the pooled analysis were supported by Keryx Biopharmaceuticals,
Inc. Keryx provided support in the form of salaries for KU and JFN, both of whom contributed
towards the design of the study and data analysis, as well as reviewing and editing
of the manuscript. The specific roles of these authors are articulated in the ‘author
contributions’ section. Robert Schupp, PharmD, CMPP, of inScience Communications,
Springer Healthcare (New York, NY, USA), provided editorial support, funded by Keryx
Biopharmaceuticals, Inc.
Subject:
Research Article
Subject:
Physical Sciences
Subject:
Chemistry
Subject:
Chemical Compounds
Subject:
Phosphates
Subject:
Biology and Life Sciences
Subject:
Biochemistry
Subject:
Proteins
Subject:
Hemoglobin
Subject:
Medicine and Health Sciences
Subject:
Hematology
Subject:
Anemia
Subject:
Iron Deficiency Anemia
Subject:
Medicine and Health Sciences
Subject:
Nephrology
Subject:
Chronic Kidney Disease
Subject:
Biology and Life Sciences
Subject:
Biochemistry
Subject:
Proteins
Subject:
Protein Complexes
Subject:
Ferritin
Subject:
Medicine and health sciences
Subject:
Clinical medicine
Subject:
Clinical trials
Subject:
Phase II clinical investigation
Subject:
Medicine and health sciences
Subject:
Pharmacology
Subject:
Drug research and development
Subject:
Clinical trials
Subject:
Phase II clinical investigation
Subject:
Research and analysis methods
Subject:
Clinical trials
Subject:
Phase II clinical investigation
Subject:
Research and Analysis Methods
Subject:
Research Design
Subject:
Clinical Research Design
Subject:
Adverse Events
Subject:
Biology and Life Sciences
Subject:
Nutrition
Subject:
Nutritional Deficiencies
Subject:
Iron Deficiency
Subject:
Medicine and Health Sciences
Subject:
Nutrition
Subject:
Nutritional Deficiencies
Subject:
Iron Deficiency
